Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06646562
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged 60 Years for 24
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged 60 Years for 24
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LOVER60
Brief Summary:
People Living with HIV-1 PLHIV are an important group of patients attending their specialists and continue growing thanks to efficacy antiretroviral treatment ART allowing them to stabilize the HIV-infection and to live a normal life despite the infection The present study is encouraged to demonstrate that efficacy and security of CAB LA RPV LA treatments on this population remains the same compared to younger population of patients This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them Psychosocial aspects are also very important in these patients as these patients may suffer social stigma and therefore suffering certain psychological disorders
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None